Trial Profile

Phase I clinical trial of HG030 in China for patients with NTRK/ ROS1 gene fusion-positive cancers.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HG 030 (Primary)
Indications Cancer; Solid tumours
Focus Adverse reactions
Sponsors HitGen

Most Recent Events

21 Nov 2020 New trial record
30 Mar 2020 According to a HitGen media release, HG030 has obtained IND approval from the CDE (Center For Drug Evaluation), NMPA, Chinas Regulatory Authority for clinical trials and new products approval. The potential indications for HG030 are against the solid tumors harboring NTRK1/2/3/ROS1 fusion genes.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com